Head-to-head studies Admelog vs Humalog
Similar mean HbA1C reduction2,3
Similar mean HbA1C reduction from baseline to Week 26 in Admelog and Humalog groups, in both Type 1 and Type 2 diabetes2,3
Similar long-term safety and tolerability profiles2,3
Similar rates of patients with at least one hypoglycaemic event, regardless of the category, was observed in both Admelog and Humalog groups in Type 1 and Type 2 diabetes2,3
CI, confidence interval; EU, European Union; GIR, glucose infusion rate; HbA1c, glycated haemoglobin; INS, plasma insulin lispro concentration; PD, pharmacodynamic; PK, pharmacokinetic; T1DM, type 1 diabetes mellitus; T2DM, type 2 diabetes mellitus; UK, United Kingdom.
- Kapitza C, et al. Diabetes Obes Metab. 2017;19(5):622–7
- Garg SK, et al. Diabetes Technol Ther. 2017;19(9):516–26
- Derwahl K, et al. Diabetes Technol Ther. 2018;20(1):1–10
Always up to date?
Webinars, evidence, expert videos, peer-to-peer events… Do you want to be the first to know when new, relevant information is available? Let us know and we’ll send you a message.